Margin collapse offset by healthy underlying growth ex-exits

Overall revenue +3.3% YoY; core portfolio growth likely solid but Pril/Fa exit drag not separately quantified in call

Gross margin 34.8% vs 48.1% YoY, decline of 1330 bps corroborates severe inflation claim

CFO states ~4% price increase; RMPM cost rise 18% YoY acknowledged; pricing alone cannot bridge 13-14% inflation gap

PAT collapsed 87.9% YoY to ₹10.6 Cr from ₹85 Cr implied; Pril/Fa exit plus margin compression both material

Growth percentage stated but revenue quantum not disclosed separately; consistent with segment momentum claims

Prior: 'substantially better in H2.' Now: 'progressive rather than immediate; depends on commodity price stability.' Timeline shifted from Q3 to Q4/H2 uncertain.

Expected, but magnitude clear: Q2 overall revenue +3.3% YoY, QoQ -1.7%; core business (ex-exits) +12.4% value growth masks reported slowdown.

Board approved ₹147 Cr buyback at ₹215/share. Management reaffirmed dividend (35-50% of profit) and NPD/capex investment priorities.

Management confirmed 60-65% of cost base is crude-derivative linked; acknowledged as unresolved near-term, NPD pipeline underway to reduce dependence.

NPDs focus on higher-margin profiles. LUPs drag margins (fixed price, margin hit). Mix management and cost efficiencies are levers. Ad spend at 7.4% revenue (up 100 bps) reflects brand investment.

Exo has better equity than Pril (which was premium-priced but not premium-perceived). Confident in Exo's future. No new inorganic brand needed in dishwash segment yet.

Brand is heritage but underexploited. Current situation: competitors (Santoor, Medimix, Patanjali) at parity now. Margo is well-positioned for next phase of growth; price inflation is temporary.

RMPM cost rise ~18% YoY; 4% pricing offset by mix/efficiency, net impact 13-14% on gross margin. We avoid indiscriminate price hikes to protect affordability and market share. Calibrated pricing.

INR5,000 Cr is still the aim. FY27 is aberration given geopolitical/commodity shocks. Growth will be led by Fabric Care and new products. NPD pipeline includes lower-crude-dependency formats for margin upside.

M&A on hold; no rush. Buyback reflects confidence in long-term fundamentals. Cash generation and dividend (35-50% of profit) support growth investment. Not holding M&A deliberately.

Pril/Fa exit didn't affect distributor terms. ROI/trade terms unchanged. Working capital impact is inventory-driven (higher material costs), not credit. Debtors' days actually improved (March 15 → Sept 23 days, now trending down).

Crude dependency is acknowledged. NPD pipeline includes products with lower crude linkage. In-house brand building is being evaluated but no imminent launches. Relying on NPDs first, then M&A/internal if needed.

Reaffirmed but heavily hedged on commodity-price dependency. No quantified FY27 target. H1 ex-exits achieved 10.2% value, 6.2% volume; on track for full-year double-digit if momentum sustains.

H2 margin recovery explicitly NOT assumed unless commodity prices stabilize. Management calls recovery 'progressive,' not immediate. Timeline pushed to H2/FY28.

Current 34.8% vs prior 48.1%; no specific target given. Recovery hinges on external (commodity) factors, not just internal actions.

RMPM costs up 18% YoY; HDPE, polypropylene up 55-60%; LABSA, SLES, soap noodles all inflationary. October renewed commodity pressure signals ongoing volatility.

OPM collapsed to 2.5%, PAT down 87.9% despite 3.3% revenue growth. Management explicitly hedges H2 margin recovery on commodity-price moderation.

Pril & Fa (franchise expiry May 2026) created headwinds; revenue drag -1.7% QoQ. Reported volumes declined marginally, but exit explains discrepancy vs. core growth.

Margo (heritage brand) facing competition from Santoor, Medimix, Patanjali in natural/premium segment. Margin recovery for Personal Care constrained by competitive pricing.

60-65% of cost base is crude-derivative linked; structural, not cyclical. Geopolitical/supply-chain shocks create medium-term margin headwinds. NPD pipeline addresses this, but execution unproven.